Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
dtZ regimen in newly diagnosed multiple myeloma
NCT00263484Phase 2Completed
- Sponsor
- Gleneagles Hospital
- Start
- Dec 2005
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of zoledronic acid in multiple myeloma (MM), sponsored by Gleneagles Hospital. Primary endpoints: Response rates (RR) at 4 months and Disease progression rates at 4 months. Started Dec 2005; status: completed.
02
Drugs
zoledronic acid
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00263484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00263484.